George W. Lloyd - 09 Aug 2022 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP, Investments & GC
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd
Issuer symbol
RPRX
Transactions as of
09 Aug 2022
Transactions value $
-$915,909
Form type
4
Date filed
11 Aug 2022, 17:02
Previous filing
01 Aug 2022
Next filing
14 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$521K -11.9K -5.34% $43.92 210K 09 Aug 2022 By GWL 2020 G, LLC F1
transaction RPRX Class A Ordinary Shares Sale -$395K -9K -4.28% $43.93 201K 10 Aug 2022 By GWL 2020 G, LLC F2
holding RPRX Class A Ordinary Shares 496K 09 Aug 2022 By GWL 2013 NG, LLC
holding RPRX Class A Ordinary Shares 380K 09 Aug 2022 By GWL 2014 G, LLC
holding RPRX Class A Ordinary Shares 274K 09 Aug 2022 By IRA
holding RPRX Class A Ordinary Shares 3K 09 Aug 2022 Direct
holding RPRX Class A Ordinary Shares 4.01K 09 Aug 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on June 23, 2022.